Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Roivant's Brepocitinib Shows Promise in Rare Inflammatory Disease, Setting Stage for FDA Submission

Roivant's Brepocitinib Shows Promise in Rare Inflammatory Disease, Setting Stage for FDA Submission

Roivant Sciences and its subsidiary Priovant Therapeutics have announced positive results from a pivotal Phase III trial of brepocitinib, a dual TYK2/JAK1 inhibitor, in patients with dermatomyositis. The success of the VALOR trial positions the company to file for FDA approval in early 2026, potentially introducing a new oral treatment option for this rare inflammatory condition.

NoahAI News9/19/2025
Lexicon Advances Non-Opioid Pain Medication to Phase III Despite Initial Setback

Lexicon Advances Non-Opioid Pain Medication to Phase III Despite Initial Setback

Lexicon Pharmaceuticals is moving forward with Phase III testing of its non-opioid pain medication pilavapadin, bolstered by new post-hoc analysis data and an increasingly favorable regulatory environment for non-addictive pain treatments. The company's decision comes despite a topline miss in earlier trials, highlighting the pharmaceutical industry's growing focus on alternatives to opioids for chronic pain management.

NoahAI News9/19/2025
Roche Enters MASH Market with $3.5B Acquisition of 89bio

Roche Enters MASH Market with $3.5B Acquisition of 89bio

Roche has made a significant move into the metabolic dysfunction-associated steatohepatitis (MASH) market by agreeing to acquire 89bio for up to $3.5 billion. The deal, announced on September 18, 2025, centers around pegozafermin, 89bio's FGF21 analog currently in late-stage development for MASH.

NoahAI News9/19/2025
Pharmaceutical Industry Faces Widespread Layoffs and Restructuring Amid Market Challenges

Pharmaceutical Industry Faces Widespread Layoffs and Restructuring Amid Market Challenges

The pharmaceutical and biotech sectors continue to grapple with significant workforce reductions and strategic realignments as companies adapt to challenging market conditions and shifting priorities.Pharmaceutical giants are leading the charge in streamlining operations and reducing headcount. Merck announced plans to cut approximately 6,000 employees globally, representing about 8% of its workforce, as part of a multiyear process to generate $3 billion in savings by 2027. The company aims to reallocate resources to support the launch of up to 20 new products.

NoahAI News9/19/2025
Oral Obesity Drugs: The Next Frontier in Weight Loss Treatment

Oral Obesity Drugs: The Next Frontier in Weight Loss Treatment

The pharmaceutical industry is on the cusp of a significant breakthrough in obesity treatment, with oral weight loss medications poised to reshape the market. As the race to develop effective and convenient anti-obesity drugs intensifies, several major players are vying for a share of what Goldman Sachs predicts could be a $100 billion market by 2030.

NoahAI News9/19/2025
New Biotech Venture Firm T.Rx Capital Launches with $77.5M Fund, Backed by Industry Veterans

New Biotech Venture Firm T.Rx Capital Launches with $77.5M Fund, Backed by Industry Veterans

T.Rx Capital, a new venture capital firm co-founded by Michael Langer, son of renowned biotech entrepreneur Robert Langer, has announced the closure of its inaugural fund, raising $77.5 million. The firm aims to invest in companies operating at the intersection of technology and biology, with a focus on early-stage investments from company formation through Series B.

NoahAI News9/19/2025
Stryker and Siemens Healthineers Join Forces to Revolutionize Neurovascular Robotics

Stryker and Siemens Healthineers Join Forces to Revolutionize Neurovascular Robotics

In a groundbreaking collaboration, medical technology giants Stryker and Siemens Healthineers have announced a partnership to develop an advanced robotic system for neurovascular procedures. This innovative project aims to transform the treatment of strokes, aneurysms, and other critical brain conditions by combining Siemens Healthineers' expertise in imaging and robotics with Stryker's extensive catalog of neurovascular devices.

NoahAI News9/19/2025
J&J Launches IVL Device in Europe as Medtronic Explores New Pacing Approach for Heart Failure

J&J Launches IVL Device in Europe as Medtronic Explores New Pacing Approach for Heart Failure

Johnson & Johnson (J&J) and Medtronic have announced significant developments in their respective cardiovascular device portfolios, addressing critical needs in peripheral artery disease (PAD) and heart failure treatment.J&J has launched its Shockwave Javelin intravascular lithotripsy (IVL) catheter in Europe, targeting patients with peripheral artery disease. The device employs sound pressure waves to break down calcium deposits in severely narrowed blood vessels, addressing a persistent challenge in complex below-the-knee (BTK) revascularization procedures.

NoahAI News9/19/2025
Biogen Acquires Alcyone Therapeutics, Advancing Spinal Drug Delivery Technology

Biogen Acquires Alcyone Therapeutics, Advancing Spinal Drug Delivery Technology

Biogen has announced its acquisition of Alcyone Therapeutics for $85 million upfront, with additional payments contingent on meeting development and regulatory milestones. The deal centers on Alcyone's ThecaFlex DRx technology, an implantable device designed to revolutionize the delivery of drugs to the central nervous system.

NoahAI News9/19/2025
Blue Shield of California's Stellarus Expands Reach with New Blues Plan Partnerships

Blue Shield of California's Stellarus Expands Reach with New Blues Plan Partnerships

Blue Shield of California's health technology sister company, Stellarus, has taken a significant step forward in its mission to support nonprofit health plans. The company has secured partnerships with Blue Cross Blue Shield of Kansas and Hawaii Medical Service Association (HMSA), marking a pivotal moment in its growth strategy.

NoahAI News9/19/2025
Lilly's Mounjaro Shows Promise in Pediatric Type 2 Diabetes Trial

Lilly's Mounjaro Shows Promise in Pediatric Type 2 Diabetes Trial

Eli Lilly's dual-action GLP-1/GIP treatment Mounjaro (tirzepatide) has demonstrated effectiveness in controlling blood sugar levels in children aged 10-17 with type 2 diabetes, according to results from a recent phase 3 trial. This development marks a significant step towards expanding treatment options for a rapidly growing patient population.

NoahAI News9/19/2025
Carisma Therapeutics Faces Setbacks as Merger Falls Through and Moderna Partnership Ends

Carisma Therapeutics Faces Setbacks as Merger Falls Through and Moderna Partnership Ends

Carisma Therapeutics, a cell therapy macrophage biotech, has encountered significant challenges in its efforts to stay afloat. The company's recent attempts at a strategic merger have failed, and its partnership with Moderna has come to an end, leaving the biotech's future uncertain.

NoahAI News9/19/2025
«1...545556...67»